Head of Small Molecule Process R&D at Merck. Trying to change the world, 1 reaction at a time. Fellow of the Royal Society of Canada. Cohost @PharmToTablePod
🚨🚨🚨 New episode alert! 🚨🚨🚨
This month’s episode features our first appearance from chemists in our London site in the UK. Come learn how EREDs can be used to access Spirocycles with David, Damien and Olivia. #MerckChemistrypodcasts.apple.com/us/podcas…
I have a lot to say about the hype currently surrounding AI in total synthesis, but I will limit myself to this:
I dare those who promote AI-driven total synthesis in industry and to funding agencies to bet their savings on the success of the synthetic routes proposed by AI.
In my thirty years as a practicing synthetic chemist, having published more than 125 total syntheses as a PI, I have encountered only one case in which each step worked as planned. Everything can look good on paper (Papier ist geduldig). But, as Mike Tyson famously put it, “Everybody has a plan until they get punched in the mouth.”
How you respond to the inevitable setbacks, surprises, and insults that chemistry throws at you is precisely what makes total synthesis such a challenging and rewarding endeavor. And it is the reason why total synthesis is such a good training ground for problem solvers in academia and industry.
I do wonder, however, what all this means for writing proposals on total synthesis, which seem to be increasingly reviewed by colleagues who have little understanding of what total synthesis actually entails. Writing such proposals has always been a somewhat silly exercise, for the reasons outlined above. Evaluating them will become even more challenging in the age of Claude, when anyone can generate a seemingly convincing synthetic route on paper. The real question, of course, is what happens when that route encounters reality.
I have a lot to say about the hype currently surrounding AI in total synthesis, but I will limit myself to this:
I dare those who promote AI-driven total synthesis in industry and to funding agencies to bet their savings on the success of the synthetic routes proposed by AI.
In my thirty years as a practicing synthetic chemist, having published more than 125 total syntheses as a PI, I have encountered only one case in which each step worked as planned. Everything can look good on paper (Papier ist geduldig). But, as Mike Tyson famously put it, “Everybody has a plan until they get punched in the mouth.”
How you respond to the inevitable setbacks, surprises, and insults that chemistry throws at you is precisely what makes total synthesis such a challenging and rewarding endeavor. And it is the reason why total synthesis is such a good training ground for problem solvers in academia and industry.
I do wonder, however, what all this means for writing proposals on total synthesis, which seem to be increasingly reviewed by colleagues who have little understanding of what total synthesis actually entails. Writing such proposals has always been a somewhat silly exercise, for the reasons outlined above. Evaluating them will become even more challenging in the age of Claude, when anyone can generate a seemingly convincing synthetic route on paper. The real question, of course, is what happens when that route encounters reality.
Folks. We are playing with fire.
Bird flu is a very bad disease
Allowing it to spread unchecked among cows and increasingly people is a very bad idea
We need both @USDA and @CDCgov to take this seriously and act now
There is an active outbreak of avian flu (H5 influenza) in dairy herds in Washington State, particularly the Yakima Valley. A number of dairy workers have been infected, with at least one death. Speaking with workers, we believe the official case numbers are a vast undercount. 1/
Great quote by Mike Myers: « I think there’s nobody that is more Canadian than a Canadian that no longer lives in Canada. »
instagram.com/reel/DfpTToFzP…
ChemASAP 1.1 is live on the App Store! 🧪📱
Thanks to all of you for the amazing feedback. Here's what's new:
📚 63 journals (pick the ones you want): RSC titles incl. Chem Sci, Chem Comm, OBC, Green Chem & Chem Soc Rev, plus Inorg Chem, Anal Chem, JPCL, Chem Mater, Macromolecules, Chem Eur J, EurJOC, Adv Synth Catal, Synthesis, Synlett, med chem titles like ACS Med Chem Lett, Nat Chem Bio, Cell Chem Bio & more
👉 Swipe right to save a paper, swipe left to mark it read
🔖 Saved list and "Hide read" so you know when you're all caught up
🔓 Open-access badge on free-to-read papers
🗂️ Journal picker grouped by field, with search
🏷️ Labels that match each publisher (ASAP, Early View, In Press, Latest)
Still free, no account needed.
Android is in testing now and coming soon (if you signed up for the testing, it will go live for you this week)!
apps.apple.com/us/app/chemas…
I’ll be monitoring my own LDL, ApoB and Lp(a) to see how I respond. For me, this is another example of how advances in biology are changing medicine. Twenty years ago, statins were among our most powerful tools for preventing cardiovascular disease
When Carey Price was drafted fifth overall in the 2005 #NHLDraft, his selection caught many by surprise.
More than 20 years later, there is no surprise that his incredible career has landed him in the @HockeyHallFame! ♥️
Carey Price a reçu sa bague du Temple de la renommée samedi à Toronto!
Carey Price got his Hockey Hall of Fame custom ring on Saturday in Toronto!
#GoHabsGo
"It's so surreal. I still feel like a little kid every time I get to put on the gear. It's so special to play in this organization."
Jacob Fowler joined @sportsnetkyle after a 26-save performance in the Canadiens' win over the Maple Leafs.
When ACS shut down its mobile app, a lot of us lost the easiest way to keep up with some of the literature. Generic RSS readers are flaky, strip out images, and force you to bounce between publishers — while new chemistry papers are coming out at a firehose pace.
All most of us want is to open one app, scroll the latest ASAPs, and actually see the graphical abstracts first — because chemists read in structures, not walls of text.
So we built ChemASAP 🧪⚡
Open one app and see the newest ASAP and early-view papers (publisher agnostic), with their graphical abstracts front and center.
• Pulls crisp TOC / graphical abstracts automatically – even when a publisher's RSS feed breaks or leaves them out
• Works across publishers in one clean feed (ACS, Nature, Wiley, RSC, Cell Press/Chem, Science, and more — not locked to one house)
• Treats @ChemRxiv as a first-class journal right alongside peer-reviewed ASAPs
• Toggle only the journals you care about, tap straight to full text, or share a paper in one tap
• No account, no sign-up
100% Free for everyone.
So far, its been our go-to app for keeping track of the literature in real-time.
📱 iPhone/iPad: apps.apple.com/us/app/chemas…
💻 Web: api.baranlab.org
Reply here with ideas for how to make it better!
Shout out to @knight_chem for sponsorship and @bot for development.